The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: influenza vaccine vectors. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Innovation in pharma: influenza vaccine vectors

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Influenza vaccine vectors is a key innovation area in the pharmaceutical industry

Influenza vaccine vectors are a type of vaccine that uses an expression vector to deliver genetic material encoding a portion or whole of the influenza virus to stimulate an immune response in the host. Hemagglutinin peptide is typically encoded into the vector.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 370+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of influenza vaccine vectors.

Key players in influenza vaccine vectors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to influenza vaccine vectors

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
GSK 997 Unlock Company Profile
Johnson & Johnson 848 Unlock Company Profile
Mitsubishi Chemical Group 434 Unlock Company Profile
AstraZeneca 404 Unlock Company Profile
C. H. Boehringer Sohn 403 Unlock Company Profile
Novartis 384 Unlock Company Profile
CSL 299 Unlock Company Profile
Sanofi 299 Unlock Company Profile
Novavax 267 Unlock Company Profile
Moderna 165 Unlock Company Profile
Merck 161 Unlock Company Profile
Curevac 160 Unlock Company Profile
Baxter International 156 Unlock Company Profile
Altimmune 138 Unlock Company Profile
Pfizer 133 Unlock Company Profile
Academia Sinica 115 Unlock Company Profile
Selecta Biosciences 113 Unlock Company Profile
FluGen 105 Unlock Company Profile
Zoetis 98 Unlock Company Profile
Vir Biotechnology 97 Unlock Company Profile
Takeda Pharmaceutical 87 Unlock Company Profile
Temasek 84 Unlock Company Profile
Celltrion 79 Unlock Company Profile
Theraclone Sciences 75 Unlock Company Profile
Nitto Denko 71 Unlock Company Profile
IMV 69 Unlock Company Profile
Bavarian Nordic 63 Unlock Company Profile
FDS Pharma 62 Unlock Company Profile
Meiji 61 Unlock Company Profile
Vaxart 58 Unlock Company Profile
SEEK Group 58 Unlock Company Profile
Toko Pharmaceutical Industries 57 Unlock Company Profile
SK 56 Unlock Company Profile
Valneva 52 Unlock Company Profile
Solon Eiendom 49 Unlock Company Profile
Viridos 48 Unlock Company Profile
Eurocine Vaccines 48 Unlock Company Profile
Inovio Pharmaceuticals 47 Unlock Company Profile
Otsuka 46 Unlock Company Profile
National Resilience 45 Unlock Company Profile
Denka 45 Unlock Company Profile
Autoimmune Technologies 44 Unlock Company Profile
Eli Lilly 44 Unlock Company Profile
BiondVax Pharmaceuticals 43 Unlock Company Profile
European Molecular Biology Laboratory 42 Unlock Company Profile
Centre National de la Recherche Scientifique 40 Unlock Company Profile
Longhorn Vaccines and Diagnostics 37 Unlock Company Profile
Daiichi Sankyo 36 Unlock Company Profile
St. Jude Children’s Research Hospital 36 Unlock Company Profile
Abbott Laboratories 35 Unlock Company Profile

Source: GlobalData Patent Analytics

GSK is one of the leading patent filers in Influenza vaccine vectors. The company has filed several patents related to influenza vaccines, which use vector as the carrier. The commonly used vectors here are modified vaccinia Ankara (MVA) vector and many others.

In terms of application diversity, Vir Biotechnology leads the pack, while Moderna and Autoimmune Technologies stood in the second and third positions, respectively. By means of geographic reach, SEEK Group held the top position, followed by Selecta Biosciences and Eurocine Vaccines.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.